Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval

Amylin has agreed to a ban on direct-to-consumer advertising and other marketing restrictions for its diabetes therapy Symlin (pramlintide) as part of FDA's March 16 approval of the drug